Pfizer (NYSE:PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for ...

Turning to Wall Street, the analysts’ consensus rating for Pfizer is Hold, based on five Buy, 11 Hold, and a single Sell ...

Shares of Pfizer PFE dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026 ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Tilray Brands jumped 27.54% to close at $13.94, after trading between an intraday low of $10.50 and a high of $14.55; the ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Pfizer PFE stock has been trading above its 50-day moving average since early November, indicating a potential short-term bullish trend. The 50-day SMA is a key indicator for traders and analysts, ...

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you ...

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4. Analysts expect the health care company to report quarterly earnings at 64 cents ...